{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:49:43Z","timestamp":1788997783893,"version":"build-2803163510"},"reference-count":28,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2007,5,22]],"date-time":"2007-05-22T00:00:00Z","timestamp":1179792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2007,5,22]],"date-time":"2007-05-22T00:00:00Z","timestamp":1179792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron Clin Pract"],"abstract":"<jats:p>&lt;i&gt;Background\/Aims:&lt;\/i&gt; In patients with chronic kidney disease (CKD) receiving adequate erythropoietin therapy, the ideal dose of nandrolone decanoate (ND) to enhance muscle mass is not known. &lt;i&gt;Methods:&lt;\/i&gt; In this phase II dose-finding study, 54 patients with CKD stage 5 were randomized to either low, medium or high doses of ND (50, 100 or 200 mg\/week for 24 weeks, respectively, in males; doses halved in females), while 7 patients acted as non-randomized controls. The primary outcome measure was appendicular lean mass (ALM) by dual-energy X-ray absorptiometry. Fluid overload (hydration of the fat-free mass) and indicators of physical functioning were secondary measures. Harms were also recorded. Data were analysed using Quade\u2019s (1967) non-parametric analysis of covariance. &lt;i&gt;Results:&lt;\/i&gt; ND increased ALM in a dose-responsive manner (change scores = 0.3 \u00b1 0.3 vs. 0.8 \u00b1 0.3 vs. 1.5 \u00b1 0.5 vs. 2.1 \u00b1 0.4 kg, control vs. low vs. medium vs. high dose groups, respectively, p &lt; 0.001) with no increases in fluid overload but no consistent effect on physical functioning. The highest dose of ND (100 mg\/week) was intolerable in females because of virilizing effects. &lt;i&gt;Conclusion:&lt;\/i&gt; If goals of future studies are to improve body composition, dosing of ND up to 200 mg\/week in males and 50 mg\/week in females should be investigated. However, to realize improvements in physical functioning, future phase III trials of ND may require additional interventions such as exercise training.<\/jats:p>","DOI":"10.1159\/000103000","type":"journal-article","created":{"date-parts":[[2007,5,29]],"date-time":"2007-05-29T08:47:23Z","timestamp":1180428443000},"page":"c125-c135","source":"Crossref","is-referenced-by-count":44,"title":["Nandrolone Decanoate as Anabolic Therapy in Chronic Kidney Disease: A Randomized Phase II Dose-Finding Study"],"prefix":"10.1159","volume":"106","author":[{"given":"Jamie H.","family":"Macdonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele M.","family":"Marcora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi M.","family":"Jibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mick J.","family":"Kumwenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Lemmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2007,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093%2Foxfordjournals.ndt.a027623"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2FS1051-2276%2804%2900136-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.2003.00704.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2FS0272-6386%2800%2970202-2"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1523-1755.1999.00410.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2F18.2.333"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159%2F000083891"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1008306301255"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001%2Fjama.281.14.1275"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2006010034"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2307%2F2347378"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2307%2F2347988"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1475-097X.2004.00600.x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1440-1681.1998.tb02179.x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016%2FS0272-6386%2800%2970316-7"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016%2F0026-0495%2885%2990196-9"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.2004-1184"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1525-139X.2003.16046.x"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.0894-0959.2004.17307.x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097%2F01.ASN.0000083905.72794.E6"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1159%2F000070242"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.2002-021231"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210%2Fjc.84.8.2647"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001%2Farchinte.135.7.972"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2265.1993.tb02388.x"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199808273390903"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfi027"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093%2Fgerona%2F58.11.M1002"}],"container-title":["Nephron Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/103000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/103000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:39:22Z","timestamp":1745462362000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000103000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,22]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000103000","archive":["Portico"],"relation":{},"ISSN":["1660-2110"],"issn-type":[{"value":"1660-2110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,22]]}}}